Neurocrine (NBIX) CSO Onyia Jude Receives 3,587-Share Award

What Happened

• Onyia Jude, Chief Scientific Officer of Neurocrine Biosciences (NBIX), had 3,587 performance-restricted stock units (PRSUs) vest on September 11, 2026 (transaction code A: award/acquisition).
• To satisfy tax withholding on the vesting, 1,936 of those shares were withheld by the company (transaction code F), with the filing showing the withholding valued at $156.22 per share (total withheld ≈ $302,442).
• After withholding, Jude received a net ~1,651 shares. The total vested value (using $156.22/share) is about $560,361; net received is about $257,919. No shares were sold on the open market.

Key Details

• Transaction date: 2026-09-11 (vesting certified per footnote).
• Filing date: 2026-09-15 — filed within the required two business days following the transaction (timely).
• Transaction codes: A = award/acquisition (3,587 shares at $0 acquisition cost shown); F = shares withheld for tax (1,936 shares at $156.22).
• Shares owned after transaction: not reported in the provided filing.
• Footnotes: F1 — PRSUs vested upon achievement of performance metric certified 9/11/2026. F2 — shares were withheld by the company to satisfy tax withholding; no open-market sale occurred.

Context

• This was a vesting of performance-based restricted stock units, not an open-market purchase or sale. Withholding to cover taxes is a routine administrative step and does not indicate an insider selling shares into the market.